Shukra Pharma Peer Comparison

NSE: SHUKRAPHAR | BSE: 524632

₹55.76

₹-1.03 (-1.81%)

As on 24-Sep-2026IST

Market cap

₹2,457 Cr

Revenue (TTM)

₹75 Cr

P/E Ratio

68.1

P/B Ratio

22.4

Div. Yield

0 %

Edit

	Shukra Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	2,457	37,212	27,783	26,915	27,712
Revenue (₹ Cr)	75	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	36.05	414.00	288.22	387.35	-371.81
Net Margin (%)	45.71	11.23	14.79	26.01	-3.93
RoE (%)	46.32	8.38	29.77	25.18	-3.85
Price to Earnings	68.15	90.98	96.40	69.69	--
Price-To-Book	22.37	7.39	20.70	15.60	3.46

Income Statement (₹ Cr)

	Shukra Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	74.84	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	78.85	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	26.23	2,792.00	1,485.56	919.25	8,195.15
EBITDA	48.61	772.00	450.24	542.56	1,010.13
Depreciation	3.73	226.00	50.83	37.68	857.51
EBIT	44.88	546.00	399.41	504.88	152.62
Interest	1.26	217.00	40.84	3.77	342.73
Other Income	4.02	122.00	12.78	27.45	244.31
Exceptional Items	0.00	12.00	0.00	0.00	-216.88
Profit before Tax	47.64	463.00	371.35	528.56	-162.68
Provision for Tax	11.59	49.00	83.14	141.21	209.13
Profit after Tax	36.05	414.00	288.22	387.35	-371.81

	Shukra Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	89.83	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	4.50	1,712.00	202.03	42.40	5,044.14
Current Liabilities	23.08	1,622.00	835.87	230.82	4,758.28
Total Liabilities	117.41	8,578.00	2,326.71	1,983.96	17,723.32

	Shukra Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	33.66	5,343.00	519.60	1,026.85	10,211.52
Current Assets	83.75	2,606.00	1,681.81	881.27	7,191.66
Total Assets	117.41	8,578.00	2,326.71	1,983.96	17,723.32
Total Debt*	5.02	2,125.00	259.37	26.49	5,495.48
Net Current Assets	60.67	984.00	845.94	650.46	2,433.38
Contingent Liabilities	5.78	768.26	19.09	17.25	95.72

	Shukra Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	3.15	390.00	205.05	292.17	1,652.60
Cash Flow from Investing Activities	-14.18	-241.00	-409.72	-265.94	-826.03
Cash from Financing Activities	4.83	-54.00	283.07	4.10	-38.98
Net Cash Inflow / Outflow	-6.20	95.00	78.39	30.33	787.59

	Shukra Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	36.98	6.79	29.22	32.42	1.24
ROE (%)	46.32	8.38	29.77	25.18	-3.85
ROA (%)	35.31	4.94	24.77	21.93	-2.21
EBIT Margin (%)	59.97	15.32	20.63	34.54	1.66
Net Margin (%)	45.71	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Shukra Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	115.05	18.37	46.65	40.90	0.78
EBIT Growth (%)	343.61	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	256.23	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	-17.05	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	34.39	13.47	144.31	26.03	0.33

	Shukra Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	67.70	93.38	94.99	69.49	-88.56
Price / Book Value	22.37	7.39	20.71	15.55	3.46
Dividend Yield (%)	0.02	0.00	0.09	0.08	0.00
EV/EBITDA	50.52	50.10	61.56	49.10	31.53
Market Cap (₹ Cr)	1,328.53	19,071.62	12,753.19	20,944.75	18,108.89

	Shukra Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.04	0.31	0.11	0.02	0.53
Short term debt to equity ratio	--	0.09	0.05	0.02	0.09
Current Ratio	3.63	1.61	2.01	3.82	1.51
Quick Ratio	3.03	1.06	1.14	2.82	0.87
Interest Coverage	38.96	3.13	10.09	141.16	0.53

	Shukra Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	30.66	16.50	26.28	24.80	23.44
Asset Turnover	0.73	0.43	1.66	0.83	0.55
Receivable days	102.07	58.75	40.13	88.98	78.20
Inventory Days	76.78	75.82	60.29	56.04	93.30
Payable days	222.02	186.21	232.47	99.95	226.14
Cash Conversion Cycle	-43.18	-51.64	-132.04	45.07	-54.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.